Aimmune Therapeutics Inc (AIMT) Stock Rating Lowered by Zacks Investment Research

Aimmune Therapeutics Inc (NASDAQ:AIMT) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Aimmune Therapeutics, Inc. is a biopharmaceutical company which is engaged in the development of desensitization treatments for peanut and other food allergies. The Company’s characterized oral desensitization immunotherapy includes AR101, a product for the treatment of peanut allergy in children and adults which is in clinical trial stage. Aimmune Therapeutics, Inc. is headquartered in Brisbane, California. “

AIMT has been the subject of several other research reports. Piper Jaffray Companies reissued an “overweight” rating and issued a $40.00 price objective on shares of Aimmune Therapeutics in a report on Monday, February 13th. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Friday, December 2nd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $33.60.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Shares of Aimmune Therapeutics (NASDAQ:AIMT) traded up 0.80% on Monday, reaching $22.61. The company’s stock had a trading volume of 261,580 shares. Aimmune Therapeutics has a 12 month low of $9.77 and a 12 month high of $27.31. The firm’s 50-day moving average price is $20.11 and its 200-day moving average price is $19.52. The stock’s market cap is $958.26 million.

Aimmune Therapeutics (NASDAQ:AIMT) last announced its quarterly earnings data on Wednesday, March 15th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.47) by $0.08. On average, analysts forecast that Aimmune Therapeutics will post ($2.80) earnings per share for the current fiscal year.

Your IP Address:

Large investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its stake in shares of Aimmune Therapeutics by 72.4% in the third quarter. JPMorgan Chase & Co. now owns 182,650 shares of the company’s stock valued at $2,740,000 after buying an additional 76,675 shares during the period. TLP Group LLC raised its stake in shares of Aimmune Therapeutics by 2.5% in the third quarter. TLP Group LLC now owns 2,904,185 shares of the company’s stock valued at $43,563,000 after buying an additional 70,900 shares during the period. Baker BROS. Advisors LP purchased a new stake in shares of Aimmune Therapeutics during the third quarter valued at $10,109,000. Employees Retirement System of Texas purchased a new stake in shares of Aimmune Therapeutics during the fourth quarter valued at $3,984,000. Finally, Emerald Mutual Fund Advisers Trust raised its stake in shares of Aimmune Therapeutics by 25.7% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 418,214 shares of the company’s stock valued at $6,273,000 after buying an additional 85,589 shares during the period. 61.61% of the stock is owned by institutional investors.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Ratings for Aimmune Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply